DIRS.INFO The most relevant business & tech news

☆ This unique medical device stock is poised to pop more than 20%, Goldman Sachs says
▼ + stars: | 2024-10-04 | by ( Brian Evans | ) www.cnbc.com time to read: +1 min

Goldman Sachs says a period of underperformance for LivaNova stock could be ending and see shares gain more than 20%. Roman initiated coverage of the medical device stock with a buy rating and a $65 per share price target. Shares have advanced roughly 3% in 2024, significantly underperforming the S & P 500's nearly 20% gain. Roman ties the underperformance to "strategic shifts in the business and pipeline setbacks" for much of the year which also pressured LivaNova's earnings. LIVN YTD mountain LivaNova stock.

Persons: Goldman Sachs, David Roman, LivaNova

☆ Here's why Abbott Labs stock is getting dinged after a strong earnings beat
▼ + stars: | 2024-07-18 | by ( Zev Fima | ) www.cnbc.com time to read: +9 min

As Abbott's organic sales growth continues to shine, the market will realize both concerns are overblown. The FreeStyle Libre itself, which had 20% organic growth in the quarter, also still has plenty of runway for further growth. Investors should focus instead on the upward revision to management's full-year outlook for both top-line organic growth and earnings. The combination of Thursday's strong results and immediate decline in share price is setting up a positive risk vs. reward setup. Within Diagnostics, a small miss in molecular was more than offset by strong results in core laboratory, point of care and rapid diagnostics.

Persons: Abbott, Edwards, Robert Ford, It's, Jim Cramer's, ABT, Jim Cramer, Jim, Robert B, Ford, Ethan Miller Organizations: Abbott Labs, Abbott Laboratories, NEC, Rio, Libre, Management, Diagnostics, Devices, CNBC, Getty Locations: Missouri, Rio —, United States, U.S, Vegas, Las Vegas , Nevada

☆ Abbott Labs' surprise guidance bump is a major positive for its shareholders
▼ + stars: | 2024-04-17 | by ( Zev Fima | ) www.cnbc.com time to read: +7 min

Abbott Laboratories Why we own it : Abbott is a high-quality medtech company growing at a fast clip. As Abbott's organic sales growth continues to shine, the market will realize both concerns are overblown. We also love that EPS results on Tuesday came in above the range management had forecasted — a classic case of under-promising and over-delivering. ABT YTD mountain Abbott Laboratories YTD Organic growth was very strong, up nearly 11%, marking the fifth consecutive quarter of double-digit increases. In diagnostics, where we see the impact of the decline in Covid testing sales, organic sales increased 5.4% year over year.

Persons: —, Abbott, Edwards, Robert Ford, necrotizing, Ford, they've, Jim Cramer's, ABT, Jim Cramer, Jim Organizations: Abbott Laboratories, Revenue, Abbott, Libre, Charitable Trust, ABT, Management, NEC, Protality, TBIs, CNBC, Abbott Labs Locations: U.S

☆ Can you hack your brain? These companies are driving innovation in the field of brain stimulation
▼ + stars: | 2023-11-21 | by ( Pia Singh | ) www.cnbc.com time to read: +12 min

These forms of deep brain stimulation require a surgical procedure during which electrodes — which generate electrical impulses to control any abnormal brain activity — are implanted into certain areas of the brain. With enough advancement in the field, doctors expect brain stimulation techniques for both severe disorders and health-and-wellness purposes will ultimately become noninvasive. Three major players There are only three companies with FDA-approved deep brain stimulation, or DBS, treatments: Medtronic , Abbott Laboratories and Boston Scientific . The spinal cord stimulation, or SCS, business is a hotbed of innovation right now, deep brain stimulation also is a key area." There is still plenty of doubt, however, about the efficacy of at-home brain stimulation devices, which offer a less direct approach to brain stimulation and don't always require FDA oversight.

Persons: —, Bernstein, Lee Hambright, Hambright, Ali Rezai, Medtronic, Abbott, Rezai, Morningstar, Debbie Wang, Wang, Elon Musk, it's Elon Musk's, Casey Halpern, it's, Halpern, Taiwan's Organizations: Drug Administration, FDA, Abbott Laboratories, Boston, Rockefeller Neuroscience, West Virginia University, American Neuromodulation Society, Boston Scientific, DBS, FactSet, Neuroscience, BCI, University of Pennsylvania, TMS Locations: neuromodulation

☆ Remote workers are falling behind in one major way: They're forgetting how to hang out with people
▼ + stars: | 2023-08-20 | by ( Juliana Kaplan | ) www.businessinsider.com time to read: +8 min

But, unlike the Great Recession, there's been no rebound in chatting with each other even as more workers return to the office. All of a sudden, life and work could happen on their own terms, and where they wanted it. And some people may not want to socialize, or can't lead a social life the way they had before COVID, whether due to illness or other factors, such as increased susceptibility to disease. While quiet time and working from home might be a boon for work life, there's still the challenge of fitting socializing around it. "Now, on a Thursday I'm more likely to see people like a couple coming in and they're splitting their entrée."

Persons: hasn't, We're, Griffin Leeds, There's, I've, there's, haven't, Yvette Sheline, Emily Hessney Lynch, Lynch, It's, —, Sheline, it's, I'm Organizations: Service, Bureau of Labor Statistics, Center, Neuromodulation, University of Pennsylvania, Survey, Leeds Locations: Wall, Silicon, Brooklyn

☆ Musk's Neuralink valued at about $5 billion despite long road to market: Reuters
▼ + stars: | 2023-06-05 | by ( ) www.cnbc.com time to read: +4 min

Such so-called secondary trades are an imperfect gauge of a company's value; their volume is thin and they lack the wider market consensus of a fundraising round or initial public offering (IPO). About 85% of pre-IPO companies are currently valued in secondary trades at an average discount of 47% to their last funding round, according to data provider Caplight. In Neuralink's last known fundraising in 2021, it raised $205 million at an approximately $2 billion valuation, according to data provider Pitchbook. The maximum amount sought for the Neuralink shares marketed for sale at a $7 billion valuation was just $500,000, according to the email seen by Reuters. Sim Desai, chief executive of Hiive, an online platform where the shares are traded, said demand for Neuralink stock has been "tremendous."

Persons: Elon, Kip Ludwig, Musk, Neuralink, Sim Desai, Arun Sridhar, Sridhar, Galvani Organizations: U.S . National Institutes of Health, Reuters, U.S . Food, GSK Plc, Sciences Locations: Neuralink's, U.S

Neuralink's valuation jump in secondary trades is in sharp contrast to other startups. About 85% of pre-IPO companies are currently valued in secondary trades at an average discount of 47% to their last funding round, according to data provider Caplight. The maximum amount sought for the Neuralink shares marketed for sale at a $7 billion valuation was just $500,000, according to the email seen by Reuters. Sim Desai, chief executive of Hiive, an online platform where the shares are traded, said demand for Neuralink stock has been "tremendous." Neuralink stock that some of the employees hold has jumped around 150% in value in just two years, based on the secondary trades.

Persons: Elon, Kip Ludwig, Musk, Neuralink, Sim Desai, Arun Sridhar, Sridhar, Galvani, Rachael Levy, Marissa Taylor, Krystal Hu, Greg Roumeliotis, David Gregorio Our Organizations: U.S . National Institutes of Health, Reuters, U.S . Food, GSK Plc, Sciences, FDA, U.S . Department of Agriculture, Department of Transportation, Thomson Locations: Neuralink's, U.S, Washington ,, New York

March 27 (Reuters) - Elon Musk's brain implant company Neuralink has approached one of the biggest U.S. neurosurgery centers as a potential clinical trials partner as it prepares to test its devices on humans once regulators allow for it, according to six people familiar with the matter. Barrow has helped standardize brain implant surgeries in which the patient can remain asleep, a key step in making it more acceptable to a broad set of the population, Ponce said. This is in line with Musk's vision for Neuralink's brain chip. The billionaire CEO of Tesla Inc (TSLA.O) and majority owner of Twitter has said Neuralink's brain implants will become as ubiquitous as Lasik eye surgery. Neuralink's implant is a brain computer interface (BCI) device, which uses electrodes that penetrate the brain or sit on its surface to provide direct communication to computers.

☆ U.S. regulators rejected Elon Musk’s bid to test brain chips in humans, citing safety risks
▼ + stars: | 2023-03-02 | by ( Rachael Levy | Marisa Taylor | ) www.cnbc.com time to read: +19 min

Companies that do secure human-testing approval typically conduct at least two rounds of trials before applying for FDA approval to commercially market a device. "Everybody in the industry was saying: 'Oh my God, they're going to run straight into a brick wall,'" Ludwig said of Musk's bid for FDA approval. For example, NeuroPace, which makes the brain implant to treat epilepsy, received final FDA approval in 2013 – 16 years after the company's launch. Beyond grants, it provides access to government experts who advise on how to gain FDA approval and commercialize a device. Musk's emails to Neuralink staffers often come from his SpaceX address, said two people who reviewed them.

☆ U.S. regulators rejected Elon Musk’s bid to test brain chips in humans
▼ + stars: | 2023-03-02 | by ( ) www.reuters.com time to read: +23 min

Musk’s missed deadlines for FDA approval of Neuralink July 2019:Musk says Neuralink is aiming to receive regulatory approval for human trials of brain implants by the end of 2020. “Everybody in the industry was saying: ‘Oh my God, they’re going to run straight into a brick wall,’” Ludwig said of Musk’s bid for FDA approval. For example, NeuroPace, which makes the brain implant to treat epilepsy, received final FDA approval in 2013 – 16 years after the company’s launch. The FDA’s concerns about the battery are also potentially serious, experts in brain devices said. Still, that proposal disappointed Neuralink because it could delay progress toward final FDA approval, one of the sources said.

Search resuls for: "Neuromodulation"

10 mentions found